Best of the IN VIVO Blog (11/2008)
This article was originally published in Start Up
Executive Summary
Best of the Blog is a monthly column highlighting the best of our free online content at www.windhover.com/blog. In November, Windhover's editorial staff posted 36 articles to the site, covering biopharma, device and diagnostics R&D, business development, regulatory and commercial news. Highlights include : Fundrasing...Forget about it. Exits: Drought is an understatement. But there's new hope for biotech: In starkest terms, the regulatory system, the single biggest stumbling block to pharmaceutical success, is tilting biotech-wards.
You may also be interested in...
Private Biotech M&A Review: Has the Market Lost Steam?
In a still-frozen IPO market, acquisition has become the go-to exit for biotech VCs, but an analysis of the past four years' deals suggests the market may have peaked. Of more than 180 private biotech acquisitions since 2005, fewer than half in each year resulted in a reliable exit for investors, and those numbers are trending downward. Although the most active acquirers amounted to a list of the usual suspects, the bulk of acquisitions were conducted by a diverse set of smaller public and still-private firms. We also review the characteristics of those companies that have had success in terms of good exits for investors.
Saints or Saviors? Secondary Buyers Offer Exit for BSX, Others
Following the sale of Boston Scientific's venture portfolio, secondary buyers are positioning themselves as possible purchases of venture capital portfolios.
The New World for New Drug Approvals: Evolution in Strategies for Getting FDA Drug Approvals
Pharma is adjusting rapidly to a new regulatory world: one in which post-marketing risk management plans change the relationship of the company to doctors and patients and one where FDA's expectations for pre-marketing information about product markets are likely to expand dramatically.